Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cetuximab biosimilar by Dragonboat Biopharmaceutical (Shanghai) for Penile Cancer: Likelihood of Approval
Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Penile Cancer. According to...
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC)....
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Penile Cancer: Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Penile Cancer. According to GlobalData,...
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Renal Cell Carcinoma: Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Renal Cell Carcinoma. According to...
Cetuximab biosimilar by Dragonboat Biopharmaceutical (Shanghai) for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Head And Neck Squamous...
Cetuximab biosimilar by Dragonboat Biopharmaceutical (Shanghai) for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Esophageal Squamous Cell Carcinoma...
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Endometrial Cancer: Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Endometrial Cancer. According to GlobalData,...